Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5148 in healthy Japanese adults
NCT06639997Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azd5148 in Clostridioides difficile infection (CDI) (4 cohorts), sponsored by AstraZeneca. Primary endpoints: Adverse Events, Serious Adverse Events and 1 more. Started Oct 2024; status: completed.
02
Drugs
azd5148
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06639997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639997.